Stewart Thomas Carlton sold $9K of CGC

Stewart Thomas Carlton (See Remarks) sold 9,285 shares of Canopy Growth Corp (CGC) at $0.97 on 2026-06-17.

Original reporting
SEC EDGAR · Stewart Thomas Carlton
Published Jun 22, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGC
Neutral
medium confidence
Mentioned
$CGC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

The newest fact is the reported open-market sale details (shares, price, total value, post-transaction holdings).

02

Market read

Traders may note insider selling, but there is no accompanying fundamental update (earnings, guidance, deal, or regulatory action).

03

What to watch

The filing lacks context on total holdings, tax obligations, or whether other insiders are buying; traders should avoid over-weighting a single small sale.

Relevance 3/10Novelty 3/10Timing: after-hours/filing update on 2026-06-22 for a 2026-06-17 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Canopy Growth (CGC).

Company-level read

Ticker impact

$CGCNeutralMedium confidence
Context

Form 4 shows officer Stewart Thomas Carlton sold 9,285 shares of Canopy Growth at $0.9741 on 2026-06-17.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only unless paired with other disclosures.

Evidence & confidence

The filing is a disclosed sale (not a buy), but it is small relative to typical float and provides no new operational/regulatory/financial catalyst.

Market effects

Minimal; this is company-specific insider transaction disclosure with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Insider sales under a non-10b5-1 plan can still be driven by diversification/taxes; without follow-on buys or guidance changes, the signal may be noise.

Key entities

  • Canopy Growth Corp

    Subject of the Form 4 insider transaction disclosure.

  • Stewart Thomas Carlton

    Officer who sold 9,285 shares of CGC.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.